The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples. NGS panel detection and WGD/AS analysis were performed on the tissue. Paracancer tissue was used as a negative control and relevant information in medical records during the operation. Then we will collect clinical diagnosis and disease information through telephone follow-up after the completion of the operation.
willing to participate in the study and sign the informed consent
age ≥18 years old
researchers evaluated that it was suitable to participate in this translational study
Endometrial cancer was confirmed histologically
Received chemotherapy within 14 days prior to sample collection, or received anti-tumor drug therapy such as radiotherapy, biotherapy, endocrine therapy, targeted therapy, immunotherapy, within 21 days prior to sample collection
previously treated with KIF18A inhibitors
researchers believed that the subjects were not suitable for the translational study for other reasons
Prospective and retrospective samples were collected from September 1, 2024 to June 30, 2025, with an estimated total sample size of 110 cases, including 80 fresh tumor tissues and 30 archival tumor tissues. There were 40 TP53 mutations (high copy type) and 70 TP53 negative (MSS type).
Case-only
Cross-sectional
Not listed
microsatellite stability status
microsatellite stability status
TP53 mutation
TP53 mutation
Chromosomal instability
Chromosomal instability (Whole genome duplication, Aneuploidy)
recurrence
disease recur
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
